Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.33 |
| ▸ | SCN1A | P35498 | 4/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719620 | 0.79 | PTGER3 (0.65) | PTGER3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL20719790 | 0.77 | CD274 (0.38) | PTGER3PDCD1LG2CD274 | |
| SCHEMBL20719473 | 0.75 | PTGER3 (0.38) | PTGER3PDCD1LG2CD274 | |
| SCHEMBL20719662 | 0.75 | CD274 (0.39) | PTGER3PDCD1LG2CD274 | |
| SCHEMBL20719499 | 0.75 | PTGER3 (0.37) | PTGER3MEN1KMT2APDCD1LG2CD274 | |
| SCHEMBL20719105 | 0.74 | PTGER3 (0.49) | PTGER3 | |
| SCHEMBL20719324 | 0.74 | PTGER3 (0.39) | PTGER3PDCD1LG2CD274 | |
| SCHEMBL20719472 | 0.73 | PTGER3 (0.39) | PTGER3PDCD1LG2CD274 | |
| SCHEMBL20719293 | 0.72 | CD274 (0.45) | PDCD1LG2CD274 | |
| SCHEMBL20719706 | 0.71 | CD274 (0.42) | PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | PTGER3 1/4885GAA 3844/4885MEN1 2604/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | PTGER3 1/4885GAA 3844/4885MEN1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.